What Gotham Therapeutics does

Gotham Therapeutics is a preclinical-stage biotechnology company founded in 2017 and headquartered in New York that is building a drug discovery platform around epitranscriptomics — the systematic study of chemical modifications to RNA and the enzymes that install, remove, and read them. The company's stated mission is to discover a novel class of small-molecule therapeutics that modulate RNA-modifying enzymes, an emerging therapeutic modality with potential applications across oncology, neurological, and inflammatory diseases.

Operationally, Gotham is structured as a private, venture-backed research organization with a small scientific team (1-10 employees in the firmographic record). The company's underlying technology centers on biochemical and cellular assays against RNA-modifying enzymes, supported by medicinal chemistry to develop selective chemical matter. Because no products, clinical assets, or platform offerings are listed in the available data, the company appears to be in the early discovery phase, with its pipeline still upstream of IND-enabling studies.

Gotham's business model is consistent with a venture-backed preclinical biotech: capital is raised in discrete equity rounds to fund internal R&D, with the long-term monetization path being out-licensing of programs, co-development partnerships with larger pharmaceutical companies, or an eventual acquisition. Its only documented financing is a $54 million Series A closed in October 2018, led by Versant Ventures with Forbion Capital Partners and SR One as co-investors. Leadership consists of Founder Samie Jaffray and CEO Lee Babiss. The company has no disclosed revenue, pricing, partnerships, or commercial milestones in the available source material.

Name

Gotham Therapeutics

Website

https://gothamtx.com

Company type

Private

Founded year

2017

Headcount range

1–10 employees

Short description

Gotham Therapeutics is a preclinical-stage, New York-based biotechnology company founded in 2017 that is developing small-molecule drugs targeting RNA-modifying enzymes (epitranscriptomics) for therapeutic use.

Ownership category

akta.pro rank

Product category

Epitranscriptomic Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Epitranscriptomic drug discovery
• RNA-modifying enzyme inhibitors
• Small molecule therapeutics
• Novel drug class
• Biotech drug development

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Gotham Therapeutics is a biotechnology company focused on discovering a novel drug class that targets the epitranscriptomics machinery — the enzymes and readers responsible for chemical modifications of RNA. The company identifies and develops small-molecule therapeutics against RNA-modifying enzymes for the treatment of disease, primarily operating in early-stage drug discovery.

Product overview

The source data does not relate to Gotham Therapeutics. The domain gothamtx.com is a slot gambling review content website acquired by X41 Group in 2024, previously associated with a Therapeutics company of the same name. No product or service offerings for Gotham Therapeutics were found in the source material.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights1 record

Direct peers

• Accent Therapeutics: Direct competitor also developing small-molecule inhibitors of RNA-modifying enzymes (notably METTL3 and other m6A writers), with a substantially larger Series B/C financing base.
• Storm Therapeutics: UK-based epitranscriptomics company developing first-in-class small molecules against RNA-modifying enzymes, the closest international analogue to Gotham's scientific focus.
• Twentyeight-Seven Therapeutics: Targets RNA-modifying proteins (e.g., METTL3) for cancer therapy; one of the original entrants into the small-molecule epitranscriptomics space.
• 858 Therapeutics: Emerging epitranscriptomics player focused on small-molecule modulators of RNA-modifying enzymes in oncology and other indications.

Emerging players

• Skyhawk Therapeutics: Develops small molecules that modulate RNA splicing and RNA biology; overlapping modality of small-molecule RNA targeting with multiple pharma partnerships.
• HiberCell: Pursues therapeutic modulation of RNA modifications and biomolecular condensates in cancer; partial mechanistic overlap with Gotham's epitranscriptomic strategy.
• Arrakis Therapeutics: Discovers small molecules that target RNA structures and RNA-protein interactions; complementary rather than identical mechanism but competing for the same RNA-targeting BD budget.
• Expansion Therapeutics: Develops small-molecule RNA-targeting therapeutics, primarily for repeat-expansion disorders; comparable RNA-biology drug-discovery platform approach.

Broad incumbents

• Omega Therapeutics: Public epigenomic programming company using engineered mRNA-encoded transcription factors; a broader incumbent in the gene-expression modulation space adjacent to epitranscriptomics.
• Foghorn Therapeutics: Public chromatin-regulation company targeting dysregulated gene-expression machinery in cancer; adjacent to Gotham's RNA-biology strategy via shared interest in gene-expression modulators.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/gotham_tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gotham Therapeutics